← Patent-cliff monitor small molecule FILSPARI SPARSENTAN
Loss of exclusivity October 2037 latest FDA-listed patent expiry
Drug detail Brand name FILSPARI Active ingredient SPARSENTAN Strength 200MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2023 Marketing status RX
Listed patents Patent Expires Type 12714697 October 2037 use U-3993 9993461 March 2030 use U-4495 9662312 March 2030 use U-4495
Regulatory exclusivity Code Expires ODE-493 September 2031 ODE-389 February 2030 I-989 April 2029 NCE February 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.